Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment.
Ascierto
P A
PA
Mozzillo
N
N
Caracò
C
C
Parasole
R
R
Palmieri
G
G
Melucci
M T
MT
Botti
G
G
Castello
G
G
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008544:Melanocytes / Q000473:pathology; D008545:Melanoma / Q000145:classification / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D014411:Neoplastic Stem Cells / Q000473:pathology; D011379:Prognosis; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000145:classification / Q000473:pathology* / Q000628:therapy; D017211:Treatment Failure
D001500:BCG Vaccine; D019496:Cancer Vaccines; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins